Lila Biologics, Inc.
- Biotech or pharma, therapeutic R&D
Lila, a cutting-edge Seattle-based biotech spun out of Nobel Laureate David Baker’s lab, uses machine learning-driven protein design to create breakthrough therapies for patients.
Lila has built two unrivaled ML-powered platforms: a Targeted RadioTherapy (TRT) platform for solid tumors and a Long-Acting Injectables (LAI) platform for cardio-pulmonary diseases.
Since raising $10M in Seed financing in September 2023, Lila has built a diverse portfolio of molecules and is now uniquely positioned to deliver transformative medicines for cancer and cardio-pulmonary patients.